Solensia for Cats - 7mg/ml - Pack of 2

Description

Solensia injection for cats - 2 x 1ml Vials

Solensia for Cats offers a breakthrough in arthritis pain control for cats. By targeting NGF, this once-monthly Solensia injection helps to control the pain of arthritis in cats, improving their quality of life. With its high tolerability and efficacy, Cat Solensia is a promising treatment option for managing the chronic pain associated with arthritis in cats.

Arthritis in cats is a degenerative joint disease that causes chronic pain and discomfort. It is characterised by the progressive deterioration of the cartilage that cushions the joints. As the disease progresses, the cartilage wears away, leading to painful bone-on-bone contact. Symptoms of arthritis in cats can include reduced mobility, reluctance to jump or climb, changes in grooming habits, and changes in behaviour.

Solensia is a highly specific treatment, functioning like naturally occurring antibodies. It is eliminated via normal protein degradation pathways, with minimal involvement of the liver or kidneys. This makes Solensia for Cats a well-tolerated treatment option, even for cats identified as IRIS stage 1 or 2, which refers to the early stages of kidney disease.

Dosage and administration

For subcutaneous use. Avoid excessive shaking or foaming of Solensia. Administer the entire content (1ml) of the vial. The recommended dose is 1-2.8 mg/kg bodyweight, once a month.

It's important to note that Solensia for Cats should not be used in breeding cats or in pregnant or lactating queens. It should also not be administered to cats with known hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection site pain.

Do not use Solensia in cases of hypersensitivity to the active substance or to any of the excipients. Do not use in animals under 12 months and/or under 2.5 kg body weight. Do not use Solensia in animals intended for breeding. Do not use Solensia in pregnant or lactating animals.

Continuation of treatment should be based on the individual response of each animal to Solensia. If a positive response is not observed, consider alternative treatments. Solensia may induce transient or persistent anti-drug antibodies. The induction of such antibodies may reduce the efficacy of the product although this was not observed during the 84 days of the pivotal clinical trial. No information is available for longer duration treatment. The safety and efficacy of Solensia has not been investigated in cats with kidney disease IRIS stages 3 and 4. Use of Solensia in such cases should be based on a benefit-risk assessment performed by the responsible veterinarian.

The safety of Solensia has not been established during pregnancy and lactation or in breeding cats. Laboratory studies with human anti-NGF antibodies in cynomolgus monkeys have shown evidence of teratogenic and foetotoxic effects. There are no safety data on the concurrent use of non-sterodal anti-inflammatory drugs (NSAIDs) and frunevetmab in the cat.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions

Store Solensia in a refrigerator (2°C - 8°C). Do not freeze. Store Solensia in the original package. Protect from light. Shelf life after first opening the immediate packaging: use immediately Keep out of the sight and reach of children. For animal treatment only.

Legal category:

Solensia is a POM-V (Pet Presription Required)

Frunevetmab, like endogenous proteins, is expected to be degraded into small peptides and amino acids via normal catabolic pathways. Solensia is not metabolised by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely. Field trials In clinical trials up to 3 months, treatment of cats with osteoarthritis was demonstrated to have a favourable effect on the reduction of pain assessed by CSOM (Client-Specific Outcome Measures). CSOM is an assessment of an individual cat’s response to pain treatment, as assessed by performance of physical activities, sociability and quality of life. The maximum total CSOM score was 15. A total of 182 animals were enrolled in the Solensia treatment group and 93 animals included in the placebo group, in the pivotal field trial. Treatment success, defined as a reduction of ≥2 in the total CSOM score and no increase in any individual score, was achieved in 66.70%, 75.91% and 76.47% of the Solensia-treated cats and in 52.06%, 64.65% and 68.09% of placebo-treated cats after one, two and three monthly treatments, respectively. Statistically significant difference (p<0.05) compared to placebo-treatment was demonstrated after the first and second treatment, but not after the third treatment.

Disposal advice. Any unused Solensia or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.